<?xml version="1.0" ?>
<document id="3e337761fbc884c46ccd834207c310a1b78f0e42">
  <chunk id="3e337761fbc884c46ccd834207c310a1b78f0e42.c0" text="Luciferase-Based Detection of Antibodies for the Diagnosis of HPV-Associated Head and Neck Squamous Cell Carcinoma">
    <entity charOffset="91-114" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c0.e0" ontology_id="HP_0002860" text="Squamous Cell Carcinoma" type="phenotype"/>
    <entity charOffset="105-114" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c0.e1" ontology_id="HP_0030731" text="Carcinoma" type="phenotype"/>
  </chunk>
  <chunk id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1" text="Point-of-care tests are needed for the screening of head and neck squamous cell carcinoma (HNSCC) and other malignancies. Luciferase immunoprecipitation systems (LIPS), employing light-emitting proteins, were used to examine serum antibodies against several cancer-associated targets in blood donor controls and subjects with colon cancer (CC) and HNSCC. The assessment of antibodies against the wild type p53 tumor antigen showed that approximately 25% of the CC and 20% of the HNSCC patients were seropositive. In addition, humoral responses against two p53 mutants, p53-R175H and p53-R273H, generally tracked the antibody responses seen against wild type p53. Analysis of antibodies against highly specific biomarkers of HPV-16-associated malignancy, E2, E6, and E7 oncoproteins, revealed no seropositivity in blood donors and CC patients. However, 45% (9/20) of the HNSCC patients showed E6 seropositivity, which overlapped all the detectable E2 (40%; 8/20) and E7 seropositive subjects (35%; 7/20). Using neodymium magnets, ultrarapid LIPSTICKS testing of HPV-16 E6 antibodies in &lt;60 s per HNSCC sample demonstrated almost the same diagnostic performance (40% sensitivity and 100% specificity) as LIPS testing in 2.5 h. While additional improvements and standardization are needed, these results highlight the possibility of using these approaches for the diagnosis of HPV-16-associated HNSCC.">
    <entity charOffset="66-89" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e0" ontology_id="HP_0002860" text="squamous cell carcinoma" type="phenotype"/>
    <entity charOffset="80-89" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e1" ontology_id="HP_0030731" text="carcinoma" type="phenotype"/>
    <entity charOffset="326-338" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e2" ontology_id="HP_0003003" text="colon cancer" type="phenotype"/>
    <entity charOffset="332-338" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e3" ontology_id="HP_0002664" text="cancer" type="phenotype"/>
    <entity charOffset="410-415" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e4" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="616-624" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" ontology_id="GO_0003823" text="antibody" type="gene_function"/>
    <entity charOffset="616-624" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" ontology_id="GO_0042571" text="antibody" type="gene_function"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e0" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p0" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e0" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p1" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e1" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p2" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e1" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p3" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e2" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p4" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e2" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p5" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e3" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p6" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e3" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p7" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e4" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e5" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p8" relation="true"/>
    <pair e1="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e4" e2="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.e6" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c1.p9" relation="true"/>
  </chunk>
  <chunk id="3e337761fbc884c46ccd834207c310a1b78f0e42.c2" text="Keywords: tumor antigens; head and neck cancer; human papilloma virus-16 (HPV-16); luciferase immunoprecipitation systems (LIPS)">
    <entity charOffset="10-15" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c2.e0" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="54-63" id="3e337761fbc884c46ccd834207c310a1b78f0e42.c2.e1" ontology_id="HP_0012740" text="papilloma" type="phenotype"/>
  </chunk>
</document>
